ES2412388T3 - Administración intratecal de FCH después de una lesión en la médula espinal - Google Patents

Administración intratecal de FCH después de una lesión en la médula espinal Download PDF

Info

Publication number
ES2412388T3
ES2412388T3 ES08721006T ES08721006T ES2412388T3 ES 2412388 T3 ES2412388 T3 ES 2412388T3 ES 08721006 T ES08721006 T ES 08721006T ES 08721006 T ES08721006 T ES 08721006T ES 2412388 T3 ES2412388 T3 ES 2412388T3
Authority
ES
Spain
Prior art keywords
fch
protein
spinal cord
administration
cord injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08721006T
Other languages
English (en)
Spanish (es)
Inventor
Hideyuki Okano
Yoshiaki Toyama
Masaya Nakamura
Akio Iwanami
Kazuya Kitamura
Toshikazu Nakamura
Hiroshi Funakoshi
Keigo Hanada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keio University
Kringle Pharma Inc
University of Osaka NUC
Original Assignee
Osaka University NUC
Keio University
Kringle Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC, Keio University, Kringle Pharma Inc filed Critical Osaka University NUC
Application granted granted Critical
Publication of ES2412388T3 publication Critical patent/ES2412388T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES08721006T 2007-02-28 2008-02-28 Administración intratecal de FCH después de una lesión en la médula espinal Active ES2412388T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/JP2007/053804 WO2008105088A1 (fr) 2007-02-28 2007-02-28 Agent de traitement d'une lésion de la moelle épinière
WOPCT/JP2007/053804 2007-02-28
PCT/JP2008/053557 WO2008105507A1 (fr) 2007-02-28 2008-02-28 Agent thérapeutique pour lésion de la moelle épinière

Publications (1)

Publication Number Publication Date
ES2412388T3 true ES2412388T3 (es) 2013-07-11

Family

ID=39720932

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08721006T Active ES2412388T3 (es) 2007-02-28 2008-02-28 Administración intratecal de FCH después de una lesión en la médula espinal

Country Status (9)

Country Link
US (1) US8518880B2 (fr)
EP (1) EP2116255B1 (fr)
KR (2) KR20150138413A (fr)
CN (2) CN101610783B (fr)
CA (1) CA2675953C (fr)
DK (1) DK2116255T3 (fr)
ES (1) ES2412388T3 (fr)
PT (1) PT2116255E (fr)
WO (2) WO2008105088A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927493B2 (en) 2008-10-10 2015-01-06 Kringle Pharma, Inc. Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue
US9040062B2 (en) 2010-08-06 2015-05-26 Sumitomo Dainippon Pharma Co., Ltd. Preparation for treatment of spinal cord injury
KR101446711B1 (ko) * 2011-05-23 2014-10-06 아주대학교산학협력단 간세포 성장인자 유전자 및 염기성 나선-고리-나선 계열의 신경형성 전사인자 유전자가 도입된 성체 줄기세포주 및 그의 용도
WO2016039163A1 (fr) 2014-09-10 2016-03-17 クリングルファーマ株式会社 Préparation à base de hgf utilisable pour le traitement de maladies du système nerveux
US10478280B2 (en) * 2017-02-17 2019-11-19 Ethicon Llc Methods and devices for delivering and securing adjunct materials to a treatment site
US10716564B2 (en) 2017-02-17 2020-07-21 Ethicon Llc Stapling adjunct attachment
CN109535243B (zh) * 2019-01-07 2019-09-24 北京诺思兰德生物技术股份有限公司 人肝细胞生长因子突变体及其应用
CN113433324B (zh) * 2021-05-28 2022-11-18 南通大学 Nck1蛋白作为标志物在诊断脊髓损伤中的应用
JPWO2023167122A1 (fr) 2022-03-01 2023-09-07
KR20240162494A (ko) * 2022-03-11 2024-11-15 각고호우징 게이오기주크 척수 손상 치료제

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0678425B2 (ja) 1984-07-06 1994-10-05 和光純薬工業株式会社 重合体の新規製造法
JPH05111382A (ja) 1991-10-22 1993-05-07 Saito Signal Kenkyusho:Kk ヒト好酸球細胞株
US6143714A (en) * 1994-10-24 2000-11-07 Regeneron Pharmaceuticals, Inc. Methods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neurons
US7033608B1 (en) * 1995-05-22 2006-04-25 The United States Of America As Represented By The Secretary Of The Army “Burst-free” sustained release poly-(lactide/glycolide) microspheres
AU2002349583B2 (en) * 2001-11-28 2007-11-22 Anges Mg, Inc. Genetic remedies for neurodegenerative diseases
US20060246036A1 (en) * 2002-09-06 2006-11-02 The General Hospital Corporation Delivery of therapeutics to the brain and spinal cord
CN1250287C (zh) * 2002-11-20 2006-04-12 中国人民解放军军事医学科学院放射医学研究所 一种重组腺病毒在脑缺血、创伤修复和组织粘连治疗中的应用
JP2005035945A (ja) * 2003-07-16 2005-02-10 Cardio Corp 組織再生複合療法
EP1747277B1 (fr) 2004-04-14 2011-08-10 Agency for Science, Technology and Research Transfert de genes dans des cellules neuronales
US7696170B2 (en) * 2005-01-24 2010-04-13 Kringle Pharma Inc. Fibrosis inhibitor for implanted organ
JP2007077125A (ja) 2005-09-16 2007-03-29 Keio Gijuku 脊髄損傷治療剤
JP2007238487A (ja) 2006-03-07 2007-09-20 Osaka Univ 脊髄損傷に対する嗅粘膜移植にｈｇｆを用いた神経機能再建法

Also Published As

Publication number Publication date
EP2116255A4 (fr) 2011-05-04
DK2116255T3 (da) 2013-05-13
HK1134445A1 (en) 2010-04-30
KR20090118078A (ko) 2009-11-17
EP2116255A1 (fr) 2009-11-11
PT2116255E (pt) 2013-06-21
CN105311620A (zh) 2016-02-10
CA2675953C (fr) 2016-05-10
WO2008105507A1 (fr) 2008-09-04
EP2116255B1 (fr) 2013-04-10
WO2008105088A1 (fr) 2008-09-04
US20120021040A9 (en) 2012-01-26
KR20150138413A (ko) 2015-12-09
US8518880B2 (en) 2013-08-27
CA2675953A1 (fr) 2008-09-04
US20100081617A1 (en) 2010-04-01
CN101610783A (zh) 2009-12-23
KR101670677B1 (ko) 2016-11-01
CN101610783B (zh) 2016-11-16

Similar Documents

Publication Publication Date Title
ES2412388T3 (es) Administración intratecal de FCH después de una lesión en la médula espinal
CN102892776B (zh) 新型肽及其用途
KR20200143407A (ko) Cgrp를 억제하는데 사용하기 위한 신경독소
ES2374712T3 (es) Proteína antisecretora para uso en el tratamiento del síndrome compartimental.
KR101950916B1 (ko) 신경 질환의 치료에 적절한 hgf 제제
US9873724B2 (en) Pro-angiogenic peptides and peptide conjugates
JP5419045B2 (ja) 脊髄損傷治療薬剤
ES3041501T3 (en) Hmgb1 derived peptide for treating or preventing a cartilage disorder
HK1134445B (en) Intrathecal administration of hgf after spinal cord injury
US8927493B2 (en) Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue
JP7750489B2 (ja) Ｈｍｇｂ１部分ペプチドを含有する製剤
JP5637854B2 (ja) 腱骨移行部組織または靭帯骨移行部組織の再生促進剤
JP2007238487A (ja) 脊髄損傷に対する嗅粘膜移植にｈｇｆを用いた神経機能再建法
WO2026086901A1 (fr) Composition pharmaceutique polypeptidique pour le traitement de maladies du système nerveux et son utilisation
JPH08283174A (ja) 脊髄損傷後の神経障害に対する治療剤
JP2020026397A (ja) ＴｒｋＢアンタゴニストを含む医薬組成物
US20100286055A1 (en) Use of wnt3a for acceleration of wound healing